Brief: Spago Nanomedical Continues Recruitment In Study
March 17 (Reuters) - Spago Nanomedical AB (publ) SPAGO.ST: CONTINUES RECRUITMENT IN PHASE I/IIA TUMORAD-01 STUDY FOLLOWING POSITIVE DMC RECOMMENDATION Source text: ID:nMFN8wB6Sy Further company coverage: SPAGO.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose